Latest news

  • 07 December 2018

    Sensorion announces a publication in Hearing Research on kinetics of prestin blood levels after noise trauma-induced hearing loss. Read

  • 27 November 2018

    Sensorion announces completion of patient enrollment and dosing in Seliforant phase 2a study. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more